Clinical trials
Retinal Degeneration clinical trials
Below are recruiting retinal degeneration clinical trials, each written for real people, not researchers. We’re tracking 47 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05474729RecruitingPhase 1/Phase 2
Minocycline for chronic autoimmune eye inflammation
This trial tests whether minocycline, an antibiotic that can also reduce inflammation, helps improve chronic autoimmune uveitis and protect vision. It may help by lowering ongoing immune irritation that damages the eye.
Guangzhou, GuangdongAges 18–70 - NCT05616793RecruitingPhase 1/Phase 2
Gene therapy eye surgery for LCA5 vision loss
This Phase 1/2 study tests the safety of putting a gene medicine into the eye for people with vision loss caused by LCA5 gene mutations. It includes a treatment group and a separate group of people who do not receive the gene medicine during the study.
Philadelphia, PennsylvaniaAges 4 years+ - NCT07456826Enrolling by invitationPhase 4
Comparing two eye numbing gels for shots
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
Tyler, TexasAges 18 years+ - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT01496625Recruiting
Biobank study for retinal diseases and comparison samples
This study collects and stores blood and eye-related medical information to help researchers better understand retinal diseases, including age-related macular degeneration and diabetic retinopathy. Your samples may also be used to compare people with retinal disease to people without it.
Bethesda, MarylandAges 2–120 - NCT04289571RecruitingPhase 1
Virtual reality vision testing for people with retinal disease
This early-stage study uses virtual reality tasks to check how well a person can move and function using their eyesight. It may help researchers measure vision abilities in a way that could guide future care for retinal disease.
Bethesda, MarylandAges 5–120 - NCT07502664Recruiting
A study on vision and navigation in inherited retinal disease
This study is looking at how people with inherited retinal disease that affects peripheral vision see and move around. It will test a new way to measure vision and navigation to see if it can help doctors understand how the disease affects daily life.
Irvine, CaliforniaAges 18 years+ - NCT05147701RecruitingPhase 1
Testing stem cell treatment for NAION safety
This Phase 1 study tests whether lab-made stem cells taken from donated umbilical cord are safe for people with NAION. It mainly looks for side effects and safety rather than proving the treatment works.
St John'sAges Any age - NCT05626114RecruitingPhase 2
Study of a lab-made eye treatment after subretinal surgery
This Phase 2 study tests OpRegen, a treatment delivered during special eye surgery, for geographic atrophy related to age-related macular degeneration (GA from AMD). It also includes an imaging “substudy” that uses detailed pictures of your retina to better track safety and activity.
Beverly Hills, CaliforniaAges 50 years+ - NCT06074731Recruiting
Eye imaging study using a new scanner
This trial uses a special eye scanner to look at eye diseases. It might help doctors see eye problems more clearly.
Linz, Upper AustriaAges 5–110 - NCT07002372Recruiting
Watching a video before your first eye injection
This study tests whether watching a short video before your first eye injection helps you feel more at ease. It is for people who have never had this injection before.
Hangzhou, ZhejiangAges 18 years+ - NCT06787482RecruitingPhase 1/Phase 2
Peptide therapy for retinitis pigmentosa
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
CairoAges Any age - NCT04008121RecruitingEarly Phase 1
Testing an eye imaging drug during retinal blood-vessel photos
This early safety study tests how well and how safely an investigational dye (MB-102) works during a special eye imaging test of retinal and choroidal blood vessels. It compares it to the commonly used fluorescein dye and may help doctors refine future eye imaging approaches.
Ann Arbor, MichiganAges 18 years+ - NCT07308639Recruiting
Eye disease health data study in Germany
This study looks at health records in Germany to understand how many people have certain eye conditions like age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. It also tests new ways to use this information for research.
LeverkusenAges 18 years+ - NCT07085533Recruiting
A Study of Inherited Retinal Diseases
This study is looking at how inherited retinal diseases affect color vision over time. It may help researchers understand these conditions better and is a good fit for people with a known diagnosis who can describe what they see.
WuhanAges Any age - NCT04697095Recruiting
Testing immune cells from specific AMD eye types
This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.
LyonAges 15 years+ - NCT02435940Recruiting
Registry for inherited eye vision conditions
This study is a registry, meaning it collects information about people with inherited retinal (retina) diseases. It may help researchers learn how these conditions progress and connect you with future studies or treatments.
Columbia, MarylandAges Any age - NCT04339764RecruitingPhase 1/Phase 2
iPS cell eye transplant for dry macular degeneration
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
Baltimore, MarylandAges 55–95 - NCT07005323Recruiting
New treatment for resistant wet AMD
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
Ube, YmaguchiAges 50–85 - NCT03921931Recruiting
Test retinal responses to light in healthy eyes or eye disease
This is a small pilot study that measures how parts of the retina change before and after light stimulation. It may help researchers understand eye function in people with normal vision or specific eye conditions like glaucoma or dry age-related macular degeneration (AMD).
Vienna, State of ViennaAges 18 years+ - NCT07680244Recruiting
Testing a new tool to see retina in eye scans
This trial is testing a new software tool that helps doctors see and assess different parts of the retina in eye scans. It aims to see how well the tool works in people with and without certain retina conditions.
Tucson, ArizonaAges 18 years+ - NCT07278843Recruiting
Understanding vision loss in Usher syndrome type 1B
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
Paris, Île-de-France RegionAges 3–75 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age
Hear when a new Retinal Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for retinal degeneration?
- Yes. Clin2 currently lists 47 recruiting retinal degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a retinal degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a retinal degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.